Thrivent Financial for Lutherans cut its position in shares of Dexcom (NASDAQ:DXCM) by 7.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 147,470 shares of the medical device company’s stock after selling 12,620 shares during the quarter. Thrivent Financial for Lutherans owned about 0.17% of Dexcom worth $10,937,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. FDx Advisors Inc. lifted its stake in shares of Dexcom by 33.3% in the fourth quarter. FDx Advisors Inc. now owns 23,071 shares of the medical device company’s stock valued at $1,324,000 after buying an additional 5,764 shares in the last quarter. LMR Partners LLP bought a new position in shares of Dexcom during the fourth quarter valued at about $5,444,000. California Public Employees Retirement System lifted its position in shares of Dexcom by 3.8% during the fourth quarter. California Public Employees Retirement System now owns 134,300 shares of the medical device company’s stock valued at $7,707,000 after purchasing an additional 4,900 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Dexcom by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 800,783 shares of the medical device company’s stock valued at $45,956,000 after purchasing an additional 8,444 shares in the last quarter. Finally, American International Group Inc. bought a new position in shares of Dexcom during the fourth quarter valued at about $116,000.
DXCM has been the topic of a number of recent analyst reports. Goldman Sachs Group began coverage on shares of Dexcom in a research report on Wednesday, April 4th. They set a “sell” rating and a $57.00 price target on the stock. Northcoast Research restated a “buy” rating on shares of Dexcom in a report on Sunday, March 4th. BidaskClub downgraded shares of Dexcom from a “buy” rating to a “hold” rating in a report on Tuesday, February 27th. Bank of America started coverage on shares of Dexcom in a research note on Friday, May 11th. They issued a “buy” rating and a $100.00 target price for the company. Finally, Piper Jaffray Companies set a $60.00 target price on shares of Dexcom and gave the stock a “buy” rating in a research note on Monday, February 26th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $74.50.
In other news, Director Eric Topol sold 20,000 shares of the company’s stock in a transaction dated Tuesday, June 12th. The shares were sold at an average price of $100.10, for a total value of $2,002,000.00. Following the sale, the director now directly owns 3,695 shares of the company’s stock, valued at approximately $369,869.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kevin R. Sayer sold 17,245 shares of the company’s stock in a transaction dated Wednesday, May 9th. The stock was sold at an average price of $84.37, for a total transaction of $1,454,960.65. Following the completion of the transaction, the chief executive officer now owns 366,635 shares in the company, valued at approximately $30,932,994.95. The disclosure for this sale can be found here. Over the last three months, insiders have sold 138,375 shares of company stock worth $11,769,975. Insiders own 1.80% of the company’s stock.
Shares of DXCM traded up $0.04 during mid-day trading on Wednesday, reaching $98.82. The company’s stock had a trading volume of 799,600 shares, compared to its average volume of 1,195,784. The company has a debt-to-equity ratio of 0.79, a quick ratio of 5.42 and a current ratio of 5.83. Dexcom has a 52 week low of $42.62 and a 52 week high of $101.50. The firm has a market cap of $8.37 billion, a price-to-earnings ratio of -170.38 and a beta of -0.01.
Dexcom (NASDAQ:DXCM) last issued its earnings results on Wednesday, May 2nd. The medical device company reported ($0.32) EPS for the quarter, hitting the consensus estimate of ($0.32). Dexcom had a negative net margin of 4.30% and a negative return on equity of 9.32%. The company had revenue of $184.40 million for the quarter, compared to the consensus estimate of $172.66 million. During the same period in the previous year, the firm earned ($0.49) earnings per share. The firm’s revenue for the quarter was up 29.6% on a year-over-year basis. equities research analysts predict that Dexcom will post -0.51 earnings per share for the current year.
Dexcom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Receive News & Ratings for Dexcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dexcom and related companies with MarketBeat.com's FREE daily email newsletter.